Global Anaplastic Astrocytoma Market Research Report 2023

Anaplastic astrocytoma is a rare malignant brain tumor.

The global Anaplastic Astrocytoma market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Globally, North America contributed the highest revenues in anaplastic astrocytoma market due to deep reach of the treatments to the large number of population followed by Europe and Asia-Pacific regions as the second and third largest markets for Anaplastic astrocytoma.

This report aims to provide a comprehensive presentation of the global market for Anaplastic Astrocytoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anaplastic Astrocytoma.

The Anaplastic Astrocytoma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Anaplastic Astrocytoma market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Anaplastic Astrocytoma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Anaplastic Astrocytoma Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Temodar

1.2.3 Temozolomide

1.2.4 Matulane

1.2.5 Procarbazine

1.2.6 Others

1.3 Market by Application

1.3.1 Global Anaplastic Astrocytoma Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Pre-Registration Phase

1.3.3 Clinical Trail Phase

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Anaplastic Astrocytoma Market Perspective (2018-2029)

2.2 Anaplastic Astrocytoma Growth Trends by Region

2.2.1 Global Anaplastic Astrocytoma Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Anaplastic Astrocytoma Historic Market Size by Region (2018-2023)

2.2.3 Anaplastic Astrocytoma Forecasted Market Size by Region (2024-2029)

2.3 Anaplastic Astrocytoma Market Dynamics

2.3.1 Anaplastic Astrocytoma Industry Trends

2.3.2 Anaplastic Astrocytoma Market Drivers

2.3.3 Anaplastic Astrocytoma Market Challenges

2.3.4 Anaplastic Astrocytoma Market Restraints

3.1 Global Top Anaplastic Astrocytoma Players by Revenue

3.1.1 Global Top Anaplastic Astrocytoma Players by Revenue (2018-2023)

3.1.2 Global Anaplastic Astrocytoma Revenue Market Share by Players (2018-2023)

3.2 Global Anaplastic Astrocytoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Anaplastic Astrocytoma Revenue

3.4 Global Anaplastic Astrocytoma Market Concentration Ratio

3.4.1 Global Anaplastic Astrocytoma Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Anaplastic Astrocytoma Revenue in 2022

3.5 Anaplastic Astrocytoma Key Players Head office and Area Served

3.6 Key Players Anaplastic Astrocytoma Product Solution and Service

3.7 Date of Enter into Anaplastic Astrocytoma Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Anaplastic Astrocytoma Historic Market Size by Type (2018-2023)

4.2 Global Anaplastic Astrocytoma Forecasted Market Size by Type (2024-2029)

5.1 Global Anaplastic Astrocytoma Historic Market Size by Application (2018-2023)

5.2 Global Anaplastic Astrocytoma Forecasted Market Size by Application (2024-2029)

6.1 North America Anaplastic Astrocytoma Market Size (2018-2029)

6.2 North America Anaplastic Astrocytoma Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Anaplastic Astrocytoma Market Size by Country (2018-2023)

6.4 North America Anaplastic Astrocytoma Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Anaplastic Astrocytoma Market Size (2018-2029)

7.2 Europe Anaplastic Astrocytoma Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Anaplastic Astrocytoma Market Size by Country (2018-2023)

7.4 Europe Anaplastic Astrocytoma Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Anaplastic Astrocytoma Market Size (2018-2029)

8.2 Asia-Pacific Anaplastic Astrocytoma Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Anaplastic Astrocytoma Market Size by Region (2018-2023)

8.4 Asia-Pacific Anaplastic Astrocytoma Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Anaplastic Astrocytoma Market Size (2018-2029)

9.2 Latin America Anaplastic Astrocytoma Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Anaplastic Astrocytoma Market Size by Country (2018-2023)

9.4 Latin America Anaplastic Astrocytoma Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Anaplastic Astrocytoma Market Size (2018-2029)

10.2 Middle East & Africa Anaplastic Astrocytoma Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Anaplastic Astrocytoma Market Size by Country (2018-2023)

10.4 Middle East & Africa Anaplastic Astrocytoma Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Genentech

11.1.1 Genentech Company Detail

11.1.2 Genentech Business Overview

11.1.3 Genentech Anaplastic Astrocytoma Introduction

11.1.4 Genentech Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.1.5 Genentech Recent Development

11.2 Isarna Therapeutics

11.2.1 Isarna Therapeutics Company Detail

11.2.2 Isarna Therapeutics Business Overview

11.2.3 Isarna Therapeutics Anaplastic Astrocytoma Introduction

11.2.4 Isarna Therapeutics Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.2.5 Isarna Therapeutics Recent Development

11.3 Axelar

11.3.1 Axelar Company Detail

11.3.2 Axelar Business Overview

11.3.3 Axelar Anaplastic Astrocytoma Introduction

11.3.4 Axelar Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.3.5 Axelar Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Detail

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Anaplastic Astrocytoma Introduction

11.4.4 Pfizer Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.4.5 Pfizer Recent Development

11.5 Amgen

11.5.1 Amgen Company Detail

11.5.2 Amgen Business Overview

11.5.3 Amgen Anaplastic Astrocytoma Introduction

11.5.4 Amgen Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.5.5 Amgen Recent Development

11.6 Novartis

11.6.1 Novartis Company Detail

11.6.2 Novartis Business Overview

11.6.3 Novartis Anaplastic Astrocytoma Introduction

11.6.4 Novartis Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.6.5 Novartis Recent Development

11.7 Avid Bioservices

11.7.1 Avid Bioservices Company Detail

11.7.2 Avid Bioservices Business Overview

11.7.3 Avid Bioservices Anaplastic Astrocytoma Introduction

11.7.4 Avid Bioservices Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.7.5 Avid Bioservices Recent Development

11.8 EirGen Pharma

11.8.1 EirGen Pharma Company Detail

11.8.2 EirGen Pharma Business Overview

11.8.3 EirGen Pharma Anaplastic Astrocytoma Introduction

11.8.4 EirGen Pharma Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.8.5 EirGen Pharma Recent Development

11.9 Boehringer Ingelheim

11.9.1 Boehringer Ingelheim Company Detail

11.9.2 Boehringer Ingelheim Business Overview

11.9.3 Boehringer Ingelheim Anaplastic Astrocytoma Introduction

11.9.4 Boehringer Ingelheim Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.9.5 Boehringer Ingelheim Recent Development

11.10 Celldex Therapeutics

11.10.1 Celldex Therapeutics Company Detail

11.10.2 Celldex Therapeutics Business Overview

11.10.3 Celldex Therapeutics Anaplastic Astrocytoma Introduction

11.10.4 Celldex Therapeutics Revenue in Anaplastic Astrocytoma Business (2018-2023)

11.10.5 Celldex Therapeutics Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Anaplastic Astrocytoma Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Temodar

    Table 3. Key Players of Temozolomide

    Table 4. Key Players of Matulane

    Table 5. Key Players of Procarbazine

    Table 6. Key Players of Others

    Table 7. Global Anaplastic Astrocytoma Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Anaplastic Astrocytoma Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 9. Global Anaplastic Astrocytoma Market Size by Region (2018-2023) & (US$ Million)

    Table 10. Global Anaplastic Astrocytoma Market Share by Region (2018-2023)

    Table 11. Global Anaplastic Astrocytoma Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 12. Global Anaplastic Astrocytoma Market Share by Region (2024-2029)

    Table 13. Anaplastic Astrocytoma Market Trends

    Table 14. Anaplastic Astrocytoma Market Drivers

    Table 15. Anaplastic Astrocytoma Market Challenges

    Table 16. Anaplastic Astrocytoma Market Restraints

    Table 17. Global Anaplastic Astrocytoma Revenue by Players (2018-2023) & (US$ Million)

    Table 18. Global Anaplastic Astrocytoma Market Share by Players (2018-2023)

    Table 19. Global Top Anaplastic Astrocytoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anaplastic Astrocytoma as of 2022)

    Table 20. Ranking of Global Top Anaplastic Astrocytoma Companies by Revenue (US$ Million) in 2022

    Table 21. Global 5 Largest Players Market Share by Anaplastic Astrocytoma Revenue (CR5 and HHI) & (2018-2023)

    Table 22. Key Players Headquarters and Area Served

    Table 23. Key Players Anaplastic Astrocytoma Product Solution and Service

    Table 24. Date of Enter into Anaplastic Astrocytoma Market

    Table 25. Mergers & Acquisitions, Expansion Plans

    Table 26. Global Anaplastic Astrocytoma Market Size by Type (2018-2023) & (US$ Million)

    Table 27. Global Anaplastic Astrocytoma Revenue Market Share by Type (2018-2023)

    Table 28. Global Anaplastic Astrocytoma Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 29. Global Anaplastic Astrocytoma Revenue Market Share by Type (2024-2029)

    Table 30. Global Anaplastic Astrocytoma Market Size by Application (2018-2023) & (US$ Million)

    Table 31. Global Anaplastic Astrocytoma Revenue Market Share by Application (2018-2023)

    Table 32. Global Anaplastic Astrocytoma Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 33. Global Anaplastic Astrocytoma Revenue Market Share by Application (2024-2029)

    Table 34. North America Anaplastic Astrocytoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. North America Anaplastic Astrocytoma Market Size by Country (2018-2023) & (US$ Million)

    Table 36. North America Anaplastic Astrocytoma Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Europe Anaplastic Astrocytoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Europe Anaplastic Astrocytoma Market Size by Country (2018-2023) & (US$ Million)

    Table 39. Europe Anaplastic Astrocytoma Market Size by Country (2024-2029) & (US$ Million)

    Table 40. Asia-Pacific Anaplastic Astrocytoma Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Asia-Pacific Anaplastic Astrocytoma Market Size by Region (2018-2023) & (US$ Million)

    Table 42. Asia-Pacific Anaplastic Astrocytoma Market Size by Region (2024-2029) & (US$ Million)

    Table 43. Latin America Anaplastic Astrocytoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Latin America Anaplastic Astrocytoma Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Latin America Anaplastic Astrocytoma Market Size by Country (2024-2029) & (US$ Million)

    Table 46. Middle East & Africa Anaplastic Astrocytoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 47. Middle East & Africa Anaplastic Astrocytoma Market Size by Country (2018-2023) & (US$ Million)

    Table 48. Middle East & Africa Anaplastic Astrocytoma Market Size by Country (2024-2029) & (US$ Million)

    Table 49. Genentech Company Detail

    Table 50. Genentech Business Overview

    Table 51. Genentech Anaplastic Astrocytoma Product

    Table 52. Genentech Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 53. Genentech Recent Development

    Table 54. Isarna Therapeutics Company Detail

    Table 55. Isarna Therapeutics Business Overview

    Table 56. Isarna Therapeutics Anaplastic Astrocytoma Product

    Table 57. Isarna Therapeutics Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 58. Isarna Therapeutics Recent Development

    Table 59. Axelar Company Detail

    Table 60. Axelar Business Overview

    Table 61. Axelar Anaplastic Astrocytoma Product

    Table 62. Axelar Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 63. Axelar Recent Development

    Table 64. Pfizer Company Detail

    Table 65. Pfizer Business Overview

    Table 66. Pfizer Anaplastic Astrocytoma Product

    Table 67. Pfizer Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 68. Pfizer Recent Development

    Table 69. Amgen Company Detail

    Table 70. Amgen Business Overview

    Table 71. Amgen Anaplastic Astrocytoma Product

    Table 72. Amgen Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 73. Amgen Recent Development

    Table 74. Novartis Company Detail

    Table 75. Novartis Business Overview

    Table 76. Novartis Anaplastic Astrocytoma Product

    Table 77. Novartis Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 78. Novartis Recent Development

    Table 79. Avid Bioservices Company Detail

    Table 80. Avid Bioservices Business Overview

    Table 81. Avid Bioservices Anaplastic Astrocytoma Product

    Table 82. Avid Bioservices Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 83. Avid Bioservices Recent Development

    Table 84. EirGen Pharma Company Detail

    Table 85. EirGen Pharma Business Overview

    Table 86. EirGen Pharma Anaplastic Astrocytoma Product

    Table 87. EirGen Pharma Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 88. EirGen Pharma Recent Development

    Table 89. Boehringer Ingelheim Company Detail

    Table 90. Boehringer Ingelheim Business Overview

    Table 91. Boehringer Ingelheim Anaplastic Astrocytoma Product

    Table 92. Boehringer Ingelheim Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 93. Boehringer Ingelheim Recent Development

    Table 94. Celldex Therapeutics Company Detail

    Table 95. Celldex Therapeutics Business Overview

    Table 96. Celldex Therapeutics Anaplastic Astrocytoma Product

    Table 97. Celldex Therapeutics Revenue in Anaplastic Astrocytoma Business (2018-2023) & (US$ Million)

    Table 98. Celldex Therapeutics Recent Development

    Table 99. Research Programs/Design for This Report

    Table 100. Key Data Information from Secondary Sources

    Table 101. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Anaplastic Astrocytoma Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Anaplastic Astrocytoma Market Share by Type: 2022 VS 2029

    Figure 3. Temodar Features

    Figure 4. Temozolomide Features

    Figure 5. Matulane Features

    Figure 6. Procarbazine Features

    Figure 7. Others Features

    Figure 8. Global Anaplastic Astrocytoma Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 9. Global Anaplastic Astrocytoma Market Share by Application: 2022 VS 2029

    Figure 10. Pre-Registration Phase Case Studies

    Figure 11. Clinical Trail Phase Case Studies

    Figure 12. Anaplastic Astrocytoma Report Years Considered

    Figure 13. Global Anaplastic Astrocytoma Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 14. Global Anaplastic Astrocytoma Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 15. Global Anaplastic Astrocytoma Market Share by Region: 2022 VS 2029

    Figure 16. Global Anaplastic Astrocytoma Market Share by Players in 2022

    Figure 17. Global Top Anaplastic Astrocytoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anaplastic Astrocytoma as of 2022)

    Figure 18. The Top 10 and 5 Players Market Share by Anaplastic Astrocytoma Revenue in 2022

    Figure 19. North America Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. North America Anaplastic Astrocytoma Market Share by Country (2018-2029)

    Figure 21. United States Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Canada Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Anaplastic Astrocytoma Market Share by Country (2018-2029)

    Figure 25. Germany Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. France Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. U.K. Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Italy Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Russia Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Nordic Countries Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Anaplastic Astrocytoma Market Share by Region (2018-2029)

    Figure 33. China Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Japan Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. South Korea Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Southeast Asia Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. India Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Australia Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Anaplastic Astrocytoma Market Share by Country (2018-2029)

    Figure 41. Mexico Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Brazil Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Anaplastic Astrocytoma Market Share by Country (2018-2029)

    Figure 45. Turkey Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Saudi Arabia Anaplastic Astrocytoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Genentech Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 48. Isarna Therapeutics Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 49. Axelar Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 50. Pfizer Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 51. Amgen Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 52. Novartis Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 53. Avid Bioservices Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 54. EirGen Pharma Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 55. Boehringer Ingelheim Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 56. Celldex Therapeutics Revenue Growth Rate in Anaplastic Astrocytoma Business (2018-2023)

    Figure 57. Bottom-up and Top-down Approaches for This Report

    Figure 58. Data Triangulation

    Figure 59. Key Executives Interviewed